Matthew Ford - Jasper Therapeutics Vice Resources
| JSPRW Stock | USD 0.22 0.01 4.76% |
Executive
Matthew Ford is Vice Resources of Jasper Therapeutics
| Address | 2200 Bridge Pkwy, Redwood City, CA, United States, 94065 |
| Phone | 650 549 1400 |
| Web | https://www.jaspertherapeutics.com/ |
Jasper Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4092) % which means that it has lost $0.4092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7146) %, meaning that it generated substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Total Assets are likely to drop slightly above 63.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caroline Holda | Seres Therapeutics | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| David Ege | Seres Therapeutics | 49 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| RPh Young | Seres Therapeutics | 57 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 |
Jasper Therapeutics Leadership Team
Elected by the shareholders, the Jasper Therapeutics' board of directors comprises two types of representatives: Jasper Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jasper. The board's role is to monitor Jasper Therapeutics' management team and ensure that shareholders' interests are well served. Jasper Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jasper Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Martell, CEO President | ||
| William Lis, Ex CEO | ||
| Herbert Cross, CFO Secretary | ||
| Luca Noto, Senior Operations | ||
| Carol Zoltowski, VP Quality | ||
| Herbert CPA, CFO Secretary | ||
| Jeetinder MBA, Chief Officer | ||
| Wendy MD, Senior Medicine | ||
| Jeet MBA, Chief Officer | ||
| Patricia Carlos, Senior Quality | ||
| Matthew Ford, Vice Resources | ||
| Edwin MD, Chief Officer | ||
| Judith MD, CoFounder Director | ||
| Susan Prohaska, VP CoFounder | ||
| Kevin MD, Ex RD | ||
| David MD, Portfolio Development |
Jasper Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jasper Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Number Of Shares Shorted | 19.98 K | ||||
| EBITDA | (64.98 M) | ||||
| Net Income | (64.47 M) | ||||
| Cash And Equivalents | 16.76 M | ||||
| Cash Per Share | 1.65 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 1.96 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.